Non-Steroidal Anti-inflammatory drugs (NSAIDs) are widely employed in musculoskeletal
disease, both for their antiinflammatory as well as their analgesic properties [1]. Use of these …

Abstract Non-Steroidal Anti-inflammatory drugs (NSAIDs), including selective
cyclooxygenase (COX)-2 inhibitors, have come to play an important role in the …

Objective: To evaluate the efficacy of 12 weeks of treatment with etoricoxib, a selective COX-
2 inhibitor, in patients with osteoarthritis (OA) of the knee or hip. Methods: In the 12-week …

Objective: To further assess the clinically active dose range of etoricoxib, a COX-2 selective
inhibitor, in rheumatoid arthritis (RA). Methods: RA patients were randomized to etoricoxib …

Objectives. To evaluate the clinical efficacy and tolerability of etoricoxib in the treatment of
osteoarthritis (OA) of the knee and define the clinically active dose range for further clinical …

Etoricoxib (Arcoxia, Merck & Co., Inc.) is a selective inhibitor of cyclooxygenase-2 (COX-2),
an enzyme involved in pain and inflammation. It is a member of the COX-2-selective (coxib) …

Background Treatment with non-steroidal anti-inflammatory drugs (NSAID) is a common
component of treatment regimens for rheumatoid arthritis (RA). Etoricoxib is a COX-2 …

Etoricoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, approved in Europe for the
symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and …

Background: Osteoarthritis (OA) is most common form of arthritis; also referred as
degenerative joint disease or “wear and tear” arthritis. Cyclooxygenase-2 (COX-2) inhibitors …

Background Etoricoxib is a highly selective COX-2 inhibitor which was evaluated for the
treatment of rheumatoid arthritis (RA). Methods Double-blind, randomized, placebo and …